E.R. SAGITOVA, D.YU. RYZHKOVA, N.M. ASHRAFOVA

Orenburg State Medical University, Orenburg, Russia

 Contact:

Sagitova E.R. – Cand. Sci. (Medicine), Associate Professor of the Department of Polyclinic Therapy

Address: 6 Sovetskaya St., 460000 Orenburg, tel. +7 (912) 354-53-81, e-mail: sagel.8181@mail.ru

The article presents a case of T-cell acute lymphoblastic leukemia (T-ALL) in a patient aged 54 years, against which acute myeloid leukemia developed. The main methods of laboratory examination are given. Intensive polychemo-therapy of T-ALL in 50% of cases causes long-term remission in adults. Treatment of acute T-cell lymphoblastic leukemia consists in long-term intensive systemic chemotherapy and intrathecal administration of chemopreparations. However, despite significant achievements in treatment of patients with this pathology, relapse of the disease occurs in 40% of patients and the risk of secondary leukemia development increases.

Key words: T-cell lymphoblastic leukemia, clinical case, acute myeloid leukemia, secondary leukemia, chemotherapy, phenotype switching.

REFERENCES

1. Konstantinova T.S., Malkov N.N., Partylova E.A. Clinical case of acute leukemia with a mixed phenotype. Vestnik gematologii, 2019, no. 15 (3), pp. 29-31 (in Russ.).
2. Parovichnikova E.N, Troitskaya V.V., Gavrilina O.A. et al. Klinicheskie rekomendatsii “Ostryy limfoblastnyy leykoz”. Assotsiatsiya sodey-stviya razvitiyu gematologii i transplantologii kostnogo mozga «Natsional’noe gematologicheskoe obshchestvo», Obshcherossiyskiy natsional’nyy soyuz «Assotsiatsiya onkologov Rossii». Gruppa ekspertov-razrabotchikov, 2020 [Clinical recommendations “Acute lymphoblastic leukemia”. Association for Promoting the Development of Hematology and Bone Marrow Transplantation «National Hematological Society», All-Russian National Union «Association of Oncologists of Russia». Group of expert developers, 2020], 510 p., available at: https://oncology-association.ru/wp-content/uploads/2022/05/oll.pdf
3. Vasil’eva A.N., Aleshina O.A., Biderman B.V., Sudarikov A.B. Molecular genetic abnormalities in patients with T-cell acute lymphoblastic leukemia: a review of the literature. Onkogematologiya, 2022, no. 17 (4), pp. 166-176 (in Russ.). DOI: 10.17650/1818-8346-2022-17-4-166-176
4. Ol’khovskiy I.A., Komina A.V., Stolyar M.A., Gorbenko A.S. Molecular genetic disorders in acute leukemia as the basis for the development of diagnostic tests (literature review). Laboratornaya sluzhba, 2020, no. 9(4), pp. 26‑45 (in Russ.). DOI: 10.17116/labs2020904126
5. Wang X., Ding D., Liu Y. Acute myeloidleukemia secondary to acute B lymphoblastic leu-kemia treat-edwith maintenance therapy in a child: A case report. Cancer Reports, 2022, no. 5(11):e1717 (in Russ.). DOI: 10.1002/cnr2.
6. Afanas’ev B.V., Baranova O.Yu., Bondarenko S.N. et al. Klinicheskie rekomendatsii “Ostrye mieloidnye leykozy”. Assotsiatsiya sodey-stviya razvitiyu gematologii i transplantologii kostnogo mozga «Natsional’noe gematologicheskoe obshchestvo», Obshcherossiyskiy natsional’nyy soyuz «Assotsiatsiya onkologov Rossii». Gruppa ekspertov-razrabotchikov [Clinical guidelines “Acute myeloid leukemia”. Association for Promoting the Development of Hematology and Bone Marrow Transplantation «National Hematological Society», All-Russian National Union «Association of Oncologists of Russia». Group of expert developers], 2020, 95 p., available at: https://oncology-association.ru/wp-content/uploads/2020/09/ostrye_mieloidnye_lejkozy.pdf
7. Gavrilina O.A., Kotova E.S., Parovichnikova E.N. et al. The use of nelarabine in adult patients with refractory/relapsed acute T-lymphoblastic leukemia/lymphoma: experience from one center. Gematologiya i transfuziologiya, 2019, no. 64 (4), pp. 382-395 (in Russ.). DOI: 10.35754/0234-5730-2019-64-4-382-395
8. Marks D.I., Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood, 2017, no. 129 (9), pp. 1134-42. DOI: 10.1182/blood-2016-07-692608
9. Zerkalenkova E.A., Illarionova O.I., Kazakova A.N. et al. Change of linear differentiation in relapsed acute leukemia with rearrangement of the MLL gene (KMT2A). Literature review and case descriptions. Onkogematologiya, 2016, no. 11 (2), pp. 21-29 (in Russ.). DOI: 10.17650/1818-8346-2016-11-2-21-29